Abstract P3-06-15: Evaluation of HER family protein signaling network as a predictive biomarker for pCR for breast cancer patients treated with neratinib in the I-SPY 2 trial
Julia Wulfkuhle(University of California, San Francisco), Emanuel F. Petricoin(Center for Biologics Evaluation and Research), Denise M. Wolf, Lamorna Brown Swigart(University of California, San Francisco), Minetta C. Liu(Mayo Clinic), Douglas Yee(University of Minnesota Medical Center), Nola M. Hylton(University of California, San Francisco), Meredith Buxton(Center for Effective Global Action), Rosa I. Gallagher(George Mason University), Christina Yau(Hospital Authority), Laura J. Esserman(University of California, San Francisco), Donald A. Berry(Berry & Associates (United States)), Gillian L. Hirst(University of California, San Francisco), John W. Park(University of California, San Francisco), Melissa Paoloni(National Institutes of Health), Ashish Sanil(Berry & Associates (United States)), Laura van’t Veer(University of California, San Francisco), W. Fraser Symmans(The University of Texas MD Anderson Cancer Center), Susan Flynn(University of California System), Angela DeMichele(University of Pennsylvania)
Cited by 0